SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Johannes M. Giesinger, Jacobien M. Kieffer, Peter M. Fayers, Mogens Groenvold, Morten Aa. Petersen, Neil W. Scott, Mirjam A.G. Sprangers, Galina Velikova, Neil K. Aaronson, Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust, Journal of Clinical Epidemiology, 2016, 69, 79

    CrossRef

  2. 2
    Daniele Generali, Sergio Venturini, Carla Rognoni, Oriana Ciani, Lajos Pusztai, Sherene Loi, Guy Jerusalem, Alberto Bottini, Rosanna Tarricone, A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer, Breast Cancer Research and Treatment, 2015, 152, 1, 95

    CrossRef

  3. 3
    Tomofumi Naruse, Souichi Yanamoto, Shin-ichi Yamada, Satoshi Rokutanda, Akiko Kawakita, Goro Kawasaki, Masahiro Umeda, Anti-Tumor Effect of the Mammalian Target of Rapamycin Inhibitor Everolimus in Oral Squamous Cell Carcinoma, Pathology & Oncology Research, 2015, 21, 3, 765

    CrossRef

  4. 4
    Gabriel N. Hortobagyi, Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2, Neoplasia, 2015, 17, 3, 279

    CrossRef

  5. 5
    P. Jiménez-Fonseca, A. Carmona-Bayonas, E. Martín-Pérez, G. Crespo, R. Serrano, M. Llanos, C. Villabona, R. García-Carbonero, J. Aller, J. Capdevila, E. Grande, Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors, Cancer and Metastasis Reviews, 2015, 34, 3, 381

    CrossRef

  6. 6
    Frédéric Fiteni, Alhousseiny Pam, Amélie Anota, Dewi Vernerey, Sophie Paget-Bailly, Virginie Westeel, Franck Bonnetain, Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology, Expert Review of Anticancer Therapy, 2015, 1

    CrossRef

  7. 7
    Frédéric Fiteni, Amélie Anota, Virginie Westeel, Franck Bonnetain, La qualité de vie relative à la santé dans les essais cliniques de phase III en oncologie : de l’administration du questionnaire à l’analyse statistique, Bulletin du Cancer, 2015, 102, 4, 360

    CrossRef

  8. 8
    Saroj Niraula, Alberto Ocana, Eitan Amir, One step forward, two steps back: The story of everolimus in advanced breast cancer, The Breast, 2015, 24, 5, 529

    CrossRef

  9. 9
    Palma Fedele, Laura Orlando, Paola Schiavone, Nicola Calvani, Chiara Caliolo, Annamaria Quaranta, Angelo Nacci, Saverio Cinieri, Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer, Critical Reviews in Oncology/Hematology, 2015, 94, 3, 291

    CrossRef

  10. 10
    Sabino De Placido, Paolo Pronzato, Treatment options in HR+/HER2-advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?, Future Oncology, 2015, 11, 6, 975

    CrossRef

  11. 11
    Denise A. Yardley, Adverse Event Management of mTOR Inhibitors During Treatment of Hormone Receptor–Positive Advanced Breast Cancer: Considerations for Oncologists, Clinical Breast Cancer, 2014, 14, 5, 297

    CrossRef

  12. 12
    Amélie Anota, Antoine Barbieri, Marion Savina, Alhousseiny Pam, Sophie Gourgou-Bourgade, Franck Bonnetain, Caroline Bascoul-Mollevi, Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study, Health and Quality of Life Outcomes, 2014, 12, 1

    CrossRef

  13. 13
    J. Thaddeus Beck, Gabriel N. Hortobagyi, Mario Campone, Fabienne Lebrun, Ines Deleu, Hope S. Rugo, Barbara Pistilli, Norikazu Masuda, Lowell Hart, Bohuslav Melichar, Shaker Dakhil, Matthias Geberth, Martina Nunzi, Daniel Y. C. Heng, Thomas Brechenmacher, Mona El-Hashimy, Shyanne Douma, Francois Ringeisen, Martine Piccart, Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2, Breast Cancer Research and Treatment, 2014, 143, 3, 459

    CrossRef

  14. 14
    M. Piccart, G. N. Hortobagyi, M. Campone, K. I. Pritchard, F. Lebrun, Y. Ito, S. Noguchi, A. Perez, H. S. Rugo, I. Deleu, H. A. Burris, L. Provencher, P. Neven, M. Gnant, M. Shtivelband, C. Wu, J. Fan, W. Feng, T. Taran, J. Baselga, Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2, Annals of Oncology, 2014, 25, 12, 2357

    CrossRef

  15. 15
    I. F. Tannock, G. R. Pond, Everolimus, when combined with exemestane, adds toxicity with minimal benefit for women with breast cancer, Annals of Oncology, 2014, 25, 10, 2096

    CrossRef

  16. 16
    Mehmet A.N. Sendur, Nurullah Zengin, Sercan Aksoy, Kadri Altundag, Everolimus: a new hope for patients with breast cancer, Current Medical Research and Opinion, 2014, 30, 1, 75

    CrossRef

  17. 17
    Adam M. Brufsky, Managing Postmenopausal Women with Hormone Receptor–Positive Advanced Breast Cancer Who Progress on Endocrine Therapies with Inhibitors of the PI3K Pathway, The Breast Journal, 2014, 20, 4
  18. 18
    Rosj Gallicchio, Sabrina Giacomobono, Anna Nardelli, Teresa Pellegrino, Vittorio Simeon, Domenico Gattozzi, Francesca Maddalena, Pierpaolo Mainenti, Giovanni Storto, Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain, Journal of Bone and Mineral Metabolism, 2014, 32, 4, 434

    CrossRef

  19. 19
    Rowan T Chlebowski, Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer, Clinical Investigation, 2014, 4, 1, 19

    CrossRef

  20. 20
    Florian Huemer, Rupert Bartsch, Michael Gnant, The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer, Current Breast Cancer Reports, 2014, 6, 2, 59

    CrossRef

  21. 21
    Vakaramoko Diaby, Georges Adunlin, Askal Ayalew Ali, Rima Tawk, Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial, Breast Cancer Research and Treatment, 2014, 146, 3, 669

    CrossRef

  22. 22
    Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard, Howard A. Burris, José Baselga, Michael Gnant, Gabriel N. Hortobagyi, Mario Campone, Barbara Pistilli, Martine Piccart, Bohuslav Melichar, Katarina Petrakova, Francis P. Arena, Frans Erdkamp, Wael A. Harb, Wentao Feng, Ayelet Cahana, Tetiana Taran, David Lebwohl, Hope S. Rugo, Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis, Advances in Therapy, 2013, 30, 10, 870

    CrossRef

  23. 23
    Mario Campone, J. Thaddeus Beck, Michael Gnant, Patrick Neven, Kathleen I. Pritchard, Thomas Bachelot, Louise Provencher, Hope S. Rugo, Martine Piccart, Gabriel N. Hortobagyi, Martina Nunzi, Daniel Y.C. Heng, José Baselga, Anna Komorowski, Shinzaburo Noguchi, Jun Horiguchi, Lee Bennett, Ryan Ziemiecki, Jie Zhang, Ayelet Cahana, Tetiana Taran, Tarek Sahmoud, Howard A. Burris, Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2−advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy, Current Medical Research and Opinion, 2013, 29, 11, 1463

    CrossRef